Department of New Health Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
J Korean Med Sci. 2021 Nov 1;36(42):e271. doi: 10.3346/jkms.2021.36.e271.
We conducted a pooled analysis of the diagnostic accuracy of F-18 fluoroestradiol (F-18 FES) positron emission tomography/computed tomography (PET/CT) assessing estrogen receptor expression of patients who have recurrent or metastatic breast cancer.
Two investigators and seven related experts (from the departments of nuclear medicine, hematological oncology, surgery, and evidence-based medicine) evaluated the effectiveness of F-18 FES PET/CT according to diagnostic accuracy and correlation with immunohistochemistry tests via systematic literature review, and safety according to test-related side effects. The present study was conducted in accordance with the Scottish Intercollegiate Guidelines (SIGN), and the Cochrane, and Preferred Reporting Items for Systematic Reviews and Meta Analyses guidelines. The SIGN tools were used for quality assessment.
Of the 512 articles retrieved in the literature search, 8 were deemed to be eligible for inclusion. Results of the evaluation indicated that the F-18 FES PET/CT test was safe because patients who reported pain in the injection site in the analyzed articles are most likely to be caused by mechanical injury from needle injection not by administration of radioactive materials. Assessment of diagnostic accuracy based on data from seven studies revealed a pooled sensitivity and specificity of 0.86 and 0.85, respectively.
As such, the test was evaluated to be a safe and effective and, considering the anatomical site where only invasive tests are possible, the test was deemed to have high clinical utility.
我们对 F-18 氟雌二醇（F-18 FES）正电子发射断层扫描/计算机断层扫描（PET/CT）评估复发性或转移性乳腺癌患者雌激素受体表达的诊断准确性进行了汇总分析。
两名调查员和七名相关专家（来自核医学、血液肿瘤学、外科和循证医学系）根据诊断准确性和与免疫组织化学检测的相关性，通过系统文献回顾评估 F-18 FES PET/CT 的有效性，并根据与检测相关的副作用评估安全性。本研究符合苏格兰校际指南（SIGN）、Cochrane 和系统评价和荟萃分析的首选报告项目指南。使用 SIGN 工具进行质量评估。
在文献检索中检索到的 512 篇文章中，有 8 篇被认为符合纳入标准。评估结果表明，F-18 FES PET/CT 检测是安全的，因为分析文章中报告注射部位疼痛的患者很可能是由针注射引起的机械损伤引起的，而不是由放射性物质引起的。根据七项研究的数据评估诊断准确性，合并敏感性和特异性分别为 0.86 和 0.85。
因此，评估该检测为安全有效，并且考虑到仅可进行有创检测的解剖部位，该检测具有较高的临床实用性。
